82 results about "Rotavirus" patented technology

The invention discloses a bovine rotavirus monoclonal antibody and a preparation method of a bovine rotavirus quantum dot immunochromatography test strip, and belongs to the technical field of bovine rotavirus monoclonal antibodies. According to the invention, a hybridoma cell strain BRV 3G9 is utilized, and a monoclonal antibody is prepared by adopting an ascites method; the BRV 3G9 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.46138. The BRV 3G9 is named as BRV 3G9. According to the present invention, the concentrated live virus immunized mouse is adopted to prepare the monoclonal antibody with strong immunoreaction, and the BRV quantum dot immunochromatography test strip is researched and developed on the basis of the monoclonal antibody, and has advantages of convenient use, high efficiency, high sensitivity, strong specificity and the like, and can achieve the rapid clinical differential diagnosis of calf diarrhea pathogens, the problem that grassroots veterinarians lack a clinical rapid detection technology is solved, the diagnosis and treatment level and the prevention and treatment effect are improved, and technical guarantee is provided for efficiently preventing and treating calf diarrhea and guaranteeing calf health.

The invention belongs to the technical field of biological medicine, discloses an effect of GK921 in preparation of a drug for preventing and treating rotavirus, and finds that the GK921 can significantly inhibit RV replication, and finds that the GK921 not only inhibits transcription of rotavirus, but also can reduce expression of VP6 protein compared with the prior art. Therefore, GK921 can be used for preventing or treating rotavirus.

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

The invention discloses a multiple qPCR (quantitative polymerase chain reaction) detection reagent for detecting neonatal gastrointestinal infection pathogens. The kit comprises specific primers and probes for detecting enterohemorrhagic escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, streptococcus agalactiae, klebsiella pneumoniae, staphylococcus epidermidis, beta hemolytic streptococcus, salmonella, rotavirus and adenovirus. According to the invention, different fluorescently-labeled probes are utilized to add specific primers and probes of multiple pathogens into a reaction system to detect multiple targets at the same time, and the method has the advantages of good specificity, high sensitivity, short detection period, capability of simultaneously detecting multiple pathogens, rapidness, simplicity, convenience and economy; a convenient method is provided for rapid detection of pathogens causing neonatal gastrointestinal infection, and the kit has important significance in epidemiological research, clinical early molecular diagnosis and the like.

A single-domain antibody (sdAb) which binds to head domain of VP6 derived from a human rotavirus A and has neutralization activity against different the rotavirus A types.

The invention discloses a vaccine freeze-dried heat-resistant protective agent and a preparation method and application thereof. The freeze-dried heat-resistant protective agent consists of the following components in weight percentage: 0.6-1.0% of gelatin, 4.5-6.5% of brain heart infusion, 3.5-5.5% of tryptone, 6-10% of trehalose, 2.0-3.0% of sucrose, 1.5-2.5% of sodium thiosulfate, 0.6-1.2% of polyvinyl pyrrolidone (PVPK30), 0.4-0.6% of dextran, 0.3-0.5% of mannitol, 0.2-0.4% of glycine, 0.04-0.06% of sodium glutamate, 0.2-0.3% of L-arginine, and the balance is water for injection. The freeze-dried heat-resistant protective agent of the vaccine disclosed by the invention has components that interact with each other, thereby improving the temperature tolerance of porcine infectious gastroenteritis, porcine epidemic diarrhea and porcine rotavirus triple live vaccines during freeze-drying, reducing the loss of efficacy, and the virus loss rate before and after freeze-drying does not exceed 0.2 titers.

The invention mainly relates to a bovine rotavirus inactivated vaccine and a preparation method thereof, and according to the preparation method of the bovine rotavirus inactivated vaccine, ultrasonic emulsification conditions are as follows: the ultrasonic frequency is 24-28 kHz, the power density is controlled within the range of 0.6-0.8 W / cm, the single pulse time is 8-12 seconds, the ultrasonic time is 60-120 seconds, ultrasonic emulsification is carried out in a refrigerant bath at the temperature of 2-5 DEG C, the temperature fluctuation is + / -0.5 DEG C, and the ultrasonic time is 60-120 seconds. The virus content in the inactivated vaccine is greater than or equal to 5 * 10 < 5.0 > TCID50 / ml, and the neutralizing antibody titer within 21-49 days after secondary immunization is greater than or equal to 900. The prepared bovine rotavirus inactivated vaccine is subjected to ultrasonic emulsification, a generated neutralizing antibody can completely neutralize an RVA / Bovine-tc / CHN / SHH2023001 / 2023 / G10P [11] virus strain, the titer is high (the titer can reach 1700 or above at most), the duration time is long, the G10P [11] type bovine rotavirus is the most common virus infected in a dairy cow group, and the G10P [11] type bovine rotavirus can be used for preparing the vaccine. Therefore, the vaccine can be used as an alternative vaccine for preventing calves from being infected with bovine rotavirus.

The invention relates to the technical field related to biological medicine, and particularly provides an anti-bovine rotavirus recombinant protein vaccine composition and application thereof. The recombinant protein vaccine composition for resisting bovine rotavirus comprises a first recombinant protein vaccine which is administrated through nasal drop and a second recombinant protein vaccine which is administrated through subcutaneous injection, the first recombinant protein vaccine comprises VP6 recombinant protein and LTB recombinant protein; the second recombinant protein vaccine comprises VP7 recombinant protein. According to the recombinant protein vaccine disclosed by the invention, the combination of the first recombinant protein vaccine which is administrated through nasal dripping and the second recombinant protein vaccine which is administrated through subcutaneous injection is used, so that the comprehensiveness of preventing the bovine rotavirus is improved.

The present invention relates to a combination vaccine comprising the antigens: a) Cryptosporidium parvum gp40; b) inactivated bovine rotavirus; c) inactivated bovine coronavirus; and d) E. coli fimbrial adhesins F5 and F41. In addition, the invention relates to methods for the preparation of the vaccine, methods for vaccinating ruminants against infection by Cryptosporidium parvum, bovine rotavirus, bovine coronavirus and E. coli, and to a kit-of-parts at least comprising a container comprising the at least one antigen according to the invention.

The invention discloses an application of estramustine sodium phosphate (EMP) in preparation of a drug for treating rotavirus, and discovers that the estramustine sodium phosphate (EMP) can significantly inhibit replication of rotavirus and can play an excellent anti-rotavirus effect at a lower IC50; as the biological safety of the EMP is excellent, it is found that the EMP can almost completely inhibit rotavirus replication within the safe concentration, and it is found that the EMP not only significantly inhibits transcription of rotavirus, but also can reduce expression of VP6 protein. Thus, EMP can be used to treat rotavirus.

Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for detection of rotavirus target nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits. Methods of synthesizing the nucleic acid oligomers are also disclosed.

A composition comprising Bidens pilosa or an active compound isolated from the Bidens pilosa for use in treating, inhibiting and / or decreasing the presence of pathogenic gut microbiota in an animal in need thereof is disclosed. The pathogenic gut microbiota are at least one selected from the group consisting of Brachyspira, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV) and Rotavirus (RV). The composition is also for use in treating, inhibiting and / or decreasing occurrence of swine diarrhea, swine dysentery, swine viral infection and increasing the percentage of swine carcass and bone weight. In one embodiment, the composition is for use in treating, inhibiting and / or decreasing occurrence of swine dysentery associated with Brachyspira.

The invention belongs to the technical field of food-borne pathogenic microorganism detection, and particularly relates to an ortho-position nucleic acid probe for detecting norovirus and application of the ortho-position nucleic acid probe. The invention provides an ortho-position nucleic acid probe for identifying norovirus, the ortho-position nucleic acid probe specifically comprises a polystyrene nanoprobe and a single-chain binding protein coupling probe, and the polystyrene nanoprobe is formed by covalent binding of polystyrene microspheres, lectin and hairpin DNA. The single-chain binding protein coupling probe is formed by combining a norovirus antibody and a nucleic acid molecule through a connecting molecule. The probe is simple in synthesis condition and does not need complex purification steps. According to the present invention, a combined reaction with an activation chain, a hybridization chain reaction reagent and a catalytic self-assembly reagent is performed, and the detection sensitivity is improved through a signal cascade amplification reaction, and can achieve the minimum of 0.15 pg mL <-1 >; and moreover, the gene has excellent specificity, and the delta F'difference between the gene and pathogens of staphylococcus aureus, escherichia coli, rotavirus and astrovirus is extremely remarkable.

This invention provides a PCR primer set and method for detecting bovine rotavirus subtypes, belonging to the field of virus detection technology. The invention designs primers with high specificity and sensitivity for different bovine rotavirus subtypes. The detection method is simple to operate, can greatly shorten the typing and identification time, has high accuracy, and saves costs.

The application provides a pair of mouse monoclonal antibodies 4A5 and 2C12 with specific binding to canine rotavirus VP7 protein, and a colloidal gold detection kit prepared from the mouse monoclonal antibodies, which can detect various epidemic strains and standard strains of canine rotavirus with high sensitivity, has a high coincidence rate with an RT-PCR detection method, and can detect epidemic strains and target strains in different regions, has the advantages of rapidness, simplicity, accuracy, and can meet the urgent needs of the present clinical stage.

The present invention relates to compositions and methods for treating or preventing infectious diseases, particularly infections caused by intracellular parasites such as Cryptosporidium species. The present invention also relates to compositions and methods for treating or preventing viral or bacterial infections, particularly intestinal infections such as those caused by rotavirus and Salmonella species infections. The methods include administering a farnesyl diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat, and the composition includes a farnesyl diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat.

The present invention belongs to the field of immunology, and specifically relates to a monoclonal antibody that can neutralize different serotypes of porcine rotavirus strains. The heavy chain variable region of the monoclonal antibody includes a CDR1 with an amino acid sequence as shown in SEQ ID NO:1, a CDR2 with an amino acid sequence as shown in SEQ ID NO:2, and a CDR3 with an amino acid sequence as shown in SEQ ID NO:3; the light chain variable region of the monoclonal antibody includes a CDR1 with an amino acid sequence as shown in SEQ ID NO:4, a CDR2 with an amino acid sequence of RAS, and a CDR3 with an amino acid sequence as shown in SEQ ID NO:5. The monoclonal antibody of the present invention can effectively neutralize different serotypes of PoRV strains and inhibit their infection of cells.

The invention discloses an anti-rotavirus antibody and application thereof, and relates to the field of antibodies. The anti-rotavirus antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for rotavirus detection, and has good activity and sensitivity.

The invention discloses a G10 type bovine rotavirus nano antibody and application thereof, and belongs to the technical field of nano antibodies. The invention aims to provide the nano antibody of the G10 type bovine rotavirus. The invention provides a bovine rotavirus nano-antibody. The amino acid sequence of a CDR1 of the nano-antibody is shown as SEQ ID NO.9, the amino acid sequence of a CDR2 of the nano-antibody is shown as SEQ ID NO.10, and the amino acid sequence of a CDR3 of the nano-antibody is shown as SEQ ID NO.11. The invention further provides a preparation method of the bovine rotavirus nano-antibody. And a novel efficient strategy is provided for prevention and control of the bovine rotavirus.

The present invention belongs to the field of biomedicine and discloses the role of GK921 in the preparation of a medicament for the prevention and treatment of rotavirus. Compared with the prior art, the present invention finds that GK921 can significantly inhibit rotavirus replication and not only inhibit rotavirus transcription but also reduce VP6 protein expression. Therefore, GK921 can be used to prevent or treat rotavirus.

The invention discloses a porcine epidemic diarrhea and porcine rotavirus combined oral live vaccine diluent and a preparation method thereof, and belongs to the technical field of biological products. The porcine epidemic diarrhea and porcine rotavirus combined oral live vaccine diluent comprises component A and component B; component A comprises the following raw materials: sodium chloride, potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium alginate, chitosan, lactose and water; component B comprises the following raw materials: coptis root extract, astragalus extract, phellodendron extract, gardenia extract and water. The invention also discloses a preparation method of the porcine epidemic diarrhea and porcine rotavirus combined oral live vaccine diluent. The porcine epidemic diarrhea and porcine rotavirus combined oral live vaccine diluent prepared by the invention solves the problem that the porcine epidemic diarrhea and porcine rotavirus combined oral live vaccine is inactivated or degraded after gastric digestion, and immune protection cannot be achieved.

The present invention provides sesquiterpenoid derivatives and their application in the preparation of broad-spectrum antiviral drugs. [Solution] The present invention discloses sesquiterpenoid derivatives and their application in the preparation of broad-spectrum antiviral drugs, which stimulate heterogeneous nuclear ribonucleoprotein A2 / B1, activate the TANK-binding kinase 1-interferon regulatory factor 3 cell signal pathway, increase the secretion of endogenous type I interferon, and have inhibitory effects on various viruses. As a broad-spectrum antiviral drug, it can prevent or treat infectious diseases and illnesses caused by various viruses, including new coronavirus, vesicular stomatitis virus VSV-G, human immunodeficiency virus, hepatitis C virus, Japanese encephalitis virus, influenza virus, poliovirus, coxsackievirus, dengue virus, rotavirus, tobacco mosaic virus, measles virus, mumps virus, Ebola virus, Marburg virus, herpes virus and adenovirus. The sesquiterpenoid derivatives can be used as raw materials to prepare oral dosage forms such as tablets, capsules, drip pills, or clinically acceptable pharmaceutical preparations such as inhalants and injections.

The invention discloses a human-sheep rotavirus gene reassortment attenuated strain LG1 and application of the human-sheep rotavirus gene reassortment attenuated strain LG1. The human-sheep rotavirus gene reassortment attenuated strain LG1 comprises: i) a coding gene of a structural protein VP7 of a human G1 type rotavirus HN15D2 strain; and ii) coding genes of structural proteins VP1, VP2, VP3, VP4 and VP6 and non-structural proteins NSP1, NSP2, NSP3, NSP4 and NSP5 of the sheep rotavirus strain LLR. The human-sheep rotavirus gene reassortment strain which takes a sheep rotavirus strain as a skeleton, contains a human G1-VP7 gene and can be stably passaged on a Vero cell is successfully constructed for the first time, and the reassortment strain not only has the safety of an animal strain, but also has the immunogenicity of a human G1 type RV, can effectively prevent infection of a human G1 type wild strain, and has a good application prospect. The method has important significance for developing multivalent RV vaccines containing G1 genotypes and developing RV vaccines which are higher in prevention pertinence and provide a better protection effect on Chinese infantile diarrhea.

The present invention relates to the technical field of immunoassay analysis, and particularly relates to a method for detecting a virus and a method for preparing a colloidal gold immunochromatographic test strip. Detecting a test sample using a colloidal gold immunochromatographic test strip includes the following steps: adding the test sample to the sample pad of the colloidal gold immunochromatographic test strip, and performing an immunochromatographic reaction for 10 min - 15 min; observing the colors on the test line and the quality control line of the colloidal gold immunochromatographic test strip to obtain a test result; wherein, the colloidal gold immunochromatographic test strip includes a bottom plate, and a sample pad, a conjugate pad, a chromatographic membrane, and a water absorption pad sequentially arranged on the bottom plate, the chromatographic membrane is provided with a test line and a quality control line; the conjugate pad is coated with a rotavirus antibody labeled with colloidal gold, the particle size of the colloidal gold is 50 nm - 70 nm, the antibody at the test line includes a first antibody for recognizing a rotavirus antigen, and the antibody at the quality control line includes a second antibody for recognizing a rotavirus antibody.

The application provides application of rotavirus non-structural protein 4 in improving immune function of recombinant rotavirus subunit vaccine, wherein the application is to express the rotavirus non-structural protein 4 gene and rotavirus antigen gene in different surface rings on a norovirus P particle to obtain a recombinant protein, and the recombinant protein is the recombinant rotavirus subunit vaccine. The application improves the immune function of the recombinant rotavirus subunit vaccine by using the NSP4 protein, and parallel expression of the NSP4 gene and the VP8 antigen gene or the NSP4 antigen gene can improve the NSP4 antigen and the VP8 antigen specific IgG antibody titer, improve the neutralization ability of the VP8 antigen to the rotavirus, and improve the protection of the NSP4 antigen and the VP8 antigen to the diarrhea mice induced by the rotavirus SA11 strain.

The invention provides a bovine rotavirus VP7 protein hybridoma cell strain, a monoclonal antibody and application of the monoclonal antibody in antigen detection, and belongs to the technical field of immunodetection. The invention provides a bovine rotavirus VP7 protein hybridoma cell BRV (bovine rotavirus) Mab-VP7-23 strain, and the preservation number of the BRV Mab-VP7-23 strain is CCTCC (China Center for Type Culture Collection) NO: C2025181. The monoclonal antibody generated by the bovine rotavirus VP7 protein hybridoma cell strain BRVMab-VP7-23 can specifically recognize strains of BRV G6, G8 and G10 genotypes, does not have cross reaction with viruses such as bovine viral diarrhea / mucosal disease virus (BVDV) and the like, has good specificity, can be used for exogenous virus detection (cell inspection method) of BRV in bovine virus live vaccines, and also can be used for detecting BRV in bovine virus live vaccines. The kit can also be used for clinical detection and epidemiological investigation of BRV.

The application discloses a G10 type bovine rotavirus nanobody and application thereof, and belongs to the technical field of nanobodies. The application aims to provide a G10 type bovine rotavirus nanobody. The application provides a bovine rotavirus nanobody, wherein the amino acid sequence of CDR1 of the nanobody is shown as SEQ ID NO. 9, the amino acid sequence of CDR2 of the nanobody is shown as SEQ ID NO. 10, and the amino acid sequence of CDR3 of the nanobody is shown as SEQ ID NO. 11. The application provides a novel and efficient strategy for the prevention and control of bovine rotavirus.

The invention discloses a coupling protein as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, in-vitro self-coupling of the rotavirus VP8 protein and the norovirus VP1 protein is realized by utilizing a Spatier-Spytag system, the prepared coupled protein can induce a neutralizing antibody with higher titer aiming at the rotavirus, and the immunogenicity of the norovirus VP1 protein is not influenced; the immunized animal / human body can generate a high-titer specific IgG binding antibody, a serum blocking antibody and a neutralizing antibody aiming at the two viruses. The coupling protein has a wide application prospect in vaccines for resisting infant diarrhea viruses (norovirus and rotavirus).

The application discloses an antibody against rotavirus and application thereof, and relates to the field of antibodies. The antibody against rotavirus disclosed by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody provides an important raw material source for detection of rotavirus, and has good activity and sensitivity.